

Mark E Dudley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10714493/publications.pdf>

Version: 2024-02-01

97
papers

39,955
citations

18479

62
h-index

38392

95
g-index

98
all docs

98
docs citations

98
times ranked

24373
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. <i>Science</i> , 2002, 298, 850-854.	12.6	2,598
2	Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. <i>Science</i> , 2006, 314, 126-129.	12.6	2,352
3	Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. <i>Molecular Therapy</i> , 2010, 18, 843-851.	8.2	2,079
4	Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 4550-4557.	7.0	1,823
5	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. <i>Nature Medicine</i> , 1998, 4, 321-327.	30.7	1,693
6	Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. <i>Blood</i> , 2009, 114, 1537-1544.	1.4	1,481
7	Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. <i>Science</i> , 2014, 344, 641-645.	12.6	1,460
8	Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 2346-2357.	1.6	1,452
9	Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2011, 29, 917-924.	1.6	1,427
10	Adoptive immunotherapy for cancer: harnessing the T cell response. <i>Nature Reviews Immunology</i> , 2012, 12, 269-281.	22.7	1,412
11	Adoptive cell transfer: a clinical path to effective cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2008, 8, 299-308.	28.4	1,404
12	Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. <i>Journal of Clinical Oncology</i> , 2015, 33, 540-549.	1.6	1,397
13	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. <i>Blood</i> , 2012, 119, 2709-2720.	1.4	1,296
14	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. <i>Blood</i> , 2009, 114, 535-546.	1.4	1,280
15	Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. <i>Journal of Clinical Oncology</i> , 2008, 26, 5233-5239.	1.6	1,210
16	Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. <i>Blood</i> , 2010, 116, 4099-4102.	1.4	1,152
17	Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy. <i>Journal of Immunotherapy</i> , 2013, 36, 133-151.	2.4	953
18	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2246-2259.	8.2	892

#	ARTICLE	IF	CITATIONS
19	T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. <i>Molecular Therapy</i> , 2011, 19, 620-626.	8.2	857
20	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1â€“Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. <i>Clinical Cancer Research</i> , 2015, 21, 1019-1027.	7.0	677
21	Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients. <i>Journal of Immunotherapy</i> , 2003, 26, 332-342.	2.4	598
22	Adoptive-cell-transfer therapy for the treatment of patients with cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 666-675.	28.4	587
23	Adoptive cell therapy for the treatment of patients with metastatic melanoma. <i>Current Opinion in Immunology</i> , 2009, 21, 233-240.	5.5	539
24	Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 4129-4139.	1.4	537
25	Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirusâ€“Targeted Tumor-Infiltrating T Cells. <i>Journal of Clinical Oncology</i> , 2015, 33, 1543-1550.	1.6	513
26	Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy. <i>Journal of Immunology</i> , 2004, 173, 7125-7130.	0.8	442
27	Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression. <i>Clinical Cancer Research</i> , 2011, 17, 6287-6297.	7.0	377
28	Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. <i>Clinical Cancer Research</i> , 2014, 20, 3401-3410.	7.0	364
29	Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2001, 24, 363-373.	2.4	337
30	A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2002, 25, 243-251.	2.4	326
31	Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14639-14645.	7.1	323
32	Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 2278-2288.	7.0	310
33	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2389-2397.	1.6	293
34	Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes. <i>Journal of Immunology</i> , 2006, 177, 6548-6559.	0.8	287
35	Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. <i>Blood</i> , 2005, 105, 241-250.	1.4	273
36	CD8+ Enriched â€œYoungâ€“Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 6122-6131.	7.0	269

#	ARTICLE	IF	CITATIONS
37	Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy. <i>Journal of Immunotherapy</i> , 2008, 31, 742-751.	2.4	236
38	High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens. <i>Journal of Immunology</i> , 2003, 171, 3287-3295.	0.8	219
39	Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions. <i>Human Gene Therapy</i> , 2005, 16, 457-472.	2.7	218
40	Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy. <i>Journal of Immunotherapy</i> , 2005, 28, 53-62.	2.4	198
41	Randomized Selection Design Trial Evaluating CD8 ⁺ -Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2152-2159.	1.6	196
42	Levels of peripheral CD4 ⁺ FoxP3 ⁺ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. <i>Blood</i> , 2012, 119, 5688-5696.	1.4	176
43	Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression. <i>Journal of Immunotherapy</i> , 2005, 28, 258-267.	2.4	171
44	TIL therapy broadens the tumor-reactive CD8 ⁺ T cell compartment in melanoma patients. <i>Oncolmmunology</i> , 2012, 1, 409-418.	4.6	171
45	Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy. <i>Clinical Cancer Research</i> , 2010, 16, 4892-4898.	7.0	166
46	Cutting Edge: CD4 ⁺ T Cell Control of CD8 ⁺ T Cell Reactivity to a Model Tumor Antigen. <i>Journal of Immunology</i> , 2000, 164, 562-565.	0.8	161
47	Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. <i>Journal of Immunology</i> , 2013, 190, 6034-6042.	0.8	145
48	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. <i>Journal of Immunotherapy</i> , 2002, 25, 243-51.	2.4	139
49	Adoptive Cell Therapy for Patients with Melanoma, Using Tumor-Infiltrating Lymphocytes Genetically Engineered to Secrete Interleukin-2. <i>Human Gene Therapy</i> , 2008, 19, 496-510.	2.7	119
50	Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion. <i>Journal of Immunology</i> , 2006, 177, 6527-6539.	0.8	116
51	T Cells Associated with Tumor Regression Recognize Frameshifted Products of the <i>CDKN2A</i> Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product. <i>Journal of Immunology</i> , 2004, 172, 6057-6064.	0.8	114
52	Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment. <i>Journal of Immunotherapy</i> , 2012, 35, 283-292.	2.4	114
53	Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL. <i>Journal of Immunotherapy</i> , 2010, 33, 840-847.	2.4	113
54	Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. , 2017, 5, 85.		102

#	ARTICLE	IF	CITATIONS
55	Adoptive Cell Transfer Therapy. <i>Seminars in Oncology</i> , 2007, 34, 524-531.	2.2	100
56	Functional Heterogeneity of Vaccine-Induced CD8+ T Cells. <i>Journal of Immunology</i> , 2002, 168, 5933-5942.	0.8	89
57	Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy. <i>Journal of Immunology</i> , 2013, 191, 2217-2225.	0.8	89
58	Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma. <i>Ophthalmology</i> , 2009, 116, 981-989.e1.	5.2	88
59	Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes. <i>Journal of Immunotherapy</i> , 2012, 35, 400-408.	2.4	88
60	Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5212-5223.	7.0	87
61	Adoptive Cell Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 336-341.	2.0	86
62	Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. <i>Journal of Translational Medicine</i> , 2012, 10, 69.	4.4	84
63	Antitumor Immunization with a Minimal Peptide Epitope (G9â€“209â€“2M) Leads to a Functionally Heterogeneous CTL Response. <i>Journal of Immunotherapy</i> , 1999, 22, 288-298.	2.4	73
64	Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy. <i>Journal of Immunotherapy</i> , 2010, 33, 547-556.	2.4	64
65	Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2003, 26, 385-393.	2.4	58
66	Kinetics of TCR Use in Response to Repeated Epitope-Specific Immunization. <i>Journal of Immunology</i> , 2001, 166, 5817-5825.	0.8	56
67	Expansion and Characterization of T Cells Transduced with a Chimeric Receptor against Ovarian Cancer. <i>Human Gene Therapy</i> , 2000, 11, 2377-2387.	2.7	54
68	Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?. <i>Molecular Therapy</i> , 2012, 20, 246-249.	8.2	54
69	A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 351-362.	7.0	52
70	The Stoichiometric Production of IL-2 and IFN-Î³ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans. <i>Science Translational Medicine</i> , 2012, 4, 149ra120.	12.4	51
71	Selective Growth, In Vitro and In Vivo, of Individual T Cell Clones from Tumor-Infiltrating Lymphocytes Obtained from Patients with Melanoma. <i>Journal of Immunology</i> , 2004, 173, 7622-7629.	0.8	48
72	Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 147, 744-749.	1.9	48

#	ARTICLE	IF	CITATIONS
73	Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. <i>Clinical Cancer Research</i> , 2015, 21, 534-543.	7.0	47
74	Cancer Immunotherapy. <i>New England Journal of Medicine</i> , 2008, 359, 1072-1073.	27.0	45
75	Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. <i>Journal of Immunological Methods</i> , 2009, 345, 90-99.	1.4	40
76	Relationship of p53 Overexpression on Cancers and Recognition by Anti-p53 T Cell Receptor-Transduced T Cells. <i>Human Gene Therapy</i> , 2008, 19, 1219-1231.	2.7	38
77	A T cell receptor associated with naturally occurring human tumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19073-19078.	7.1	37
78	IRF5 gene polymorphisms in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 170.	4.4	36
79	A Simplified Method for the Clinical-scale Generation of Central Memory-like CD8+ T Cells After Transduction With Lentiviral Vectors Encoding Antitumor Antigen T-cell Receptors. <i>Journal of Immunotherapy</i> , 2010, 33, 648-658.	2.4	31
80	Bioreactors get personal. <i>Oncolmmunology</i> , 2012, 1, 1435-1437.	4.6	30
81	Evaluation of β -Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application. <i>Journal of Immunotherapy</i> , 2012, 35, 430-439.	2.4	30
82	Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy. <i>Annals of Surgical Oncology</i> , 2010, 17, 163-170.	1.5	28
83	Adoptive Cell Therapy for Patients with Melanoma. <i>Journal of Cancer</i> , 2011, 2, 360-362.	2.5	23
84	Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement. <i>Journal of Immunotherapy</i> , 2011, 34, 651-661.	2.4	19
85	Gene Mapping in a Murine Cell Line by Immunoselection with Cytotoxic T Lymphocytes. <i>Genomics</i> , 1994, 19, 273-279.	2.9	17
86	Impact of a Recombinant Fowlpox Vaccine on the Efficacy of Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes in a Patient With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2009, 32, 870-874.	2.4	16
87	Thoracic metastasectomy for adoptive immunotherapy of melanoma: A single-institution experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 140, 1276-1282.	0.8	13
88	Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100209-217 and gp100209-217T210M. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 817-24.	4.2	12
89	TCR stimulation protects CD8+ T cells from CD95 mediated apoptosis. <i>Human Immunology</i> , 2001, 62, 32-38.	2.4	11
90	Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. <i>World Journal of Surgical Oncology</i> , 2012, 10, 113.	1.9	10

#	ARTICLE	IF	CITATIONS
91	To Bead or Not to Bead. <i>Journal of Immunotherapy</i> , 2003, 26, 187-189.	2.4	6
92	Efficient Chromosomal Mapping of a Methylcholanthrene- Induced Tumor Antigen by CTL Immunoselection. <i>Journal of Immunology</i> , 2001, 167, 5143-5149.	0.8	3
93	Evaluation of chemokine-ligand pathways in pretreatment tumor biopsies as predictive biomarker of response to adoptive therapy in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8576-8576.	1.6	2
94	A stimulating presentation. <i>Nature Biotechnology</i> , 2002, 20, 125-126.	17.5	1
95	Warrior, miscreant, suicide: making better killers. <i>Blood</i> , 2007, 110, 2781-2782.	1.4	1
96	A Major Player "Gets in the Act". <i>Journal of Immunotherapy</i> , 2012, 35, 595-597.	2.4	0
97	Study of tumor-infiltrating T-cell reactivity to metastatic gastrointestinal cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14179-e14179.	1.6	0